DULUTH, Ga., May 7, 2018 /PRNewswire/ -- Sebacia, Inc., a privately held dermatology and aesthetics company, today announced a precedential ruling from the U.S. Court of Appeals for the Federal Circuit. The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc. The Federal Circuit ruled in favor of GHC deciding that the Patent Trial and Appeal Board (PTAB) was arbitrary and capricious in terminating a patent interference proceeding initiated at GHC's suggestion concerning Sienna's Patent No. 8,812,941. The Federal Circuit remanded the interference proceeding for the PTAB to determine who between GHC and Sienna was the first to invent the subject matter covered by Claim 1 of the patent.
Anthony Lando, CEO of Sebacia, commented, "We are pleased with the outcome of this precedential decision by the Federal Circuit, and we look forward to further proceedings within the PTAB focused on determining first to invent."
The referenced case is General Hospital Corp. v. Sienna Biopharmaceuticals Inc., case number 17-1012, in the U.S. Court of Appeals for the Federal Circuit.
Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia.
SOURCE Sebacia, Inc.